|
Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Cost-Effectiveness Analysis of Etanercept 25 mg Maintenance Therapy After Treatment With Etanercept 50 mg for Moderate Rheumatoid Arthritis in the PRESERVE Trial in Japan
| Title: | Cost-Effectiveness Analysis of Etanercept 25 mg Maintenance Therapy After Treatment With Etanercept 50 mg for Moderate Rheumatoid Arthritis in the PRESERVE Trial in Japan |
| Authors: | Hirose, Tomohiro Browse this author | | Kawaguchi, Isao Browse this author | | Murata, Tatsunori Browse this author | | Atsumi, Tatsuya Browse this author |
| Keywords: | cost-effectiveness analysis | | etanercept | | Japan | | maintenance therapy | | remission | | rheumatoid arthritis |
| Issue Date: | Mar-2022 |
| Publisher: | Elsevier |
| Journal Title: | Value in Health Regional Issues |
| Volume: | 28 |
| Start Page: | 105 |
| End Page: | 111 |
| Publisher DOI: | 10.1016/j.vhri.2021.06.012 |
| Abstract: | Objectives: To use Markov modeling to estimate the cost-effectiveness of treatment with etanercept 25 mg once weekly plus methotrexate (MTX) in Japanese patients with rheumatoid arthritis who had achieved remission or low disease activity with etanercept 50 mg once weekly plus MTX. Methods: Effectiveness data were estimated based on results from a clinical trial (PRESERVE) in patients with rheumatoid arthritis who had achieved remission or low disease activity and who were then randomized to receive etanercept 25 mg plus MTX or placebo plus MTX. A Markov model was established and included flare rates of 21% and 62% in the etanercept 25 mg and placebo groups, respectively. EQ-5D was calculated using an ordinary least-squares model that included the health assessment questionnaire disability index and pain visual analog scale. Worsening of the health assessment questionnaire score over 1 year was estimated to be 0.047 for patients with flare, and when associated with radiographic progression it was estimated to increase by 0.006 and 0.025 in the etanercept 25 mg and placebo groups, respectively. A cycle length of 1 year was applied to calculate the cumulative cost and effectiveness for a 10-year time span. Results: Compared with the placebo group, the quality-adjusted life-years for the etanercept 25 mg group was increased by 0.841. The incremental cost-effectiveness ratio was Y6 173 772. Conclusion: These results suggest that maintenance treatment with etanercept 25 mg is cost-effective. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/86797 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
